Log in to save to my catalogue

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-worl...

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-worl...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1882079121

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

About this item

Full title

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

Publisher

New York: Springer US

Journal title

Breast cancer research and treatment, 2017-06, Vol.163 (3), p.587-594

Language

English

Formats

Publication information

Publisher

New York: Springer US

More information

Scope and Contents

Contents

Aim
This retrospective analysis focused on the effect of treatment with EVE/EXE in a real-world population outside of clinical trials. We examined the efficacy of this combination in terms of PFS and RR related to dose intensity (5 mg daily versus 10 mg daily) and tolerability.
Methods
163 HER2-negative ER+/PgR+ ABC patients, treated with...

Alternative Titles

Full title

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1882079121

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1882079121

Other Identifiers

ISSN

0167-6806

E-ISSN

1573-7217

DOI

10.1007/s10549-017-4213-9

How to access this item